Neuromuscular Unit, Department of Pediatric Neurology, Hospital Sant Joan de Déu and Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
Pediatr Neurol. 2021 Jun;119:40-44. doi: 10.1016/j.pediatrneurol.2021.03.005. Epub 2021 Mar 26.
The ATP7A gene encodes a copper transporter whose mutations cause Menkes disease, occipital horn syndrome (OHS), and, less frequently, ATP7A-related distal hereditary motor neuropathy (dHMN). Here we describe a family with OHS caused by a novel mutation in the ATP7A gene, including a patient with a comorbid dHMN that worsened markedly after being treated with copper histidinate.
We studied in detail the clinical features of the patients and performed a genomic analysis by using TruSight One Expanded Sequencing Panel. Subsequently, we determined the ATP7A and ATP7B expression levels, mitochondrial membrane potential, and redox balance in cultured fibroblasts of Patient 1.
We found a novel ATP7A late truncated mutation p.Lys1412AsnfsX15 in the two affected members of this family. The co-occurrence of OHS and dHMN in Patient 1 reveals the variable phenotypic expressivity of the variant. A severe clinical and neurophysiologic worsening was observed in the dHMN of Patient 1 when he was treated with copper replacement therapy, with a subsequent fast recovery after the copper histidinate was withdrawn. Functional studies revealed that the patient had low levels of both ATP7A and ATP7B, the other copper transporter, and high levels of superoxide ion in the mitochondria.
Our findings broaden the clinical spectrum of ATP7A-related disorders and demonstrate that two clinical phenotypes can occur in the same patient. The copper-induced toxicity and low levels of both ATP7A and ATP7B in our patient suggest that copper accumulation in motor neurons is the pathogenic mechanism in ATP7A-related dHMN.
ATP7A 基因编码一种铜转运蛋白,其突变可导致 Menkes 病、枕骨角综合征(OHS),以及较少见的 ATP7A 相关远端遗传性运动神经病(dHMN)。本研究描述了一个由 ATP7A 基因突变引起 OHS 的家系,包括一名伴有并发 dHMN 的患者,其在接受铜组氨酸治疗后病情明显恶化。
我们详细研究了患者的临床特征,并通过 TruSight One Expanded Sequencing Panel 进行了基因组分析。随后,我们测定了患者 1 的成纤维细胞中 ATP7A 和 ATP7B 的表达水平、线粒体膜电位和氧化还原平衡。
我们在该家系的两名受累成员中发现了一个新的 ATP7A 晚期截断突变 p.Lys1412AsnfsX15。患者 1 的 OHS 和 dHMN 同时发生表明该变异具有可变的表型表达。当患者 1 接受铜替代治疗时,其 dHMN 出现严重的临床和神经生理学恶化,随后在停用铜组氨酸后迅速恢复。功能研究显示,该患者的 ATP7A 和 ATP7B 水平均较低,另一种铜转运蛋白,以及线粒体中的超氧离子水平较高。
我们的发现拓宽了 ATP7A 相关疾病的临床谱,并证明两种临床表型可出现在同一位患者中。我们患者的铜诱导毒性和 ATP7A 和 ATP7B 水平均较低提示铜在运动神经元中的蓄积是 ATP7A 相关 dHMN 的致病机制。